<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Succinylcholine (suxamethonium): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Succinylcholine (suxamethonium): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Succinylcholine (suxamethonium): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11915" href="/d/html/11915.html" rel="external">see "Succinylcholine (suxamethonium): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12809" href="/d/html/12809.html" rel="external">see "Succinylcholine (suxamethonium): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709420"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Risk of ventricular dysrhythmias, cardiac arrest, and death from hyperkalemic rhabdomyolysis in pediatric patients:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.</p>
<p style="text-indent:-2em;margin-left:2em;">When a healthy appearing pediatric patient develops cardiac arrest within minutes after administration of succinylcholine not felt to be due to inadequate ventilation, oxygenation, or anesthetic overdose, immediate treatment for hyperkalemia should be instituted. In the presence of signs of malignant hyperthermia, appropriate treatment should be instituted concurrently.</p>
<p style="text-indent:-2em;margin-left:2em;">Reserve the use of succinylcholine in pediatric patients for emergency intubation or instances where immediate securing of the airway is necessary (eg, laryngospasm, difficult airway, full stomach) or for IM use when a suitable vein is inaccessible.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F223430"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anectine;</li>
<li>Quelicin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868299"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Quelicin Chloride</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F223472"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Neuromuscular Blocker Agent, Depolarizing</li></ul></div>
<div class="block doa drugH1Div" id="F223434"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. Neuromuscular blockade does not provide pain control, sedation, or amnestic effects. Appropriate analgesic and sedative medications should be used before and during administration of neuromuscular blockade to achieve deep sedation. To avoid prolonged neuromuscular blockade, use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic abnormalities of plasma cholinesterase or associated with other conditions (eg, electrolyte abnormalities, neuromuscular disease, severe liver or kidney disease, malignant tumors).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1ce47f7b-ea74-444c-a108-17f9425fd149">Electroconvulsive therapy, muscle relaxation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Electroconvulsive therapy (ECT), muscle relaxation (off-label use): IV:</b> 0.5 to 1.5 mg/kg (doses ≥0.75 mg/kg are more common in clinical practice); adjust dose higher or lower based on muscle mass, muscle relaxation with previous ECT, and patient-specific risks associated with suboptimal relaxation (eg, increase dose in patients with osteoporosis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11973219','lexi-content-ref-26967896','lexi-content-ref-10553856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11973219','lexi-content-ref-26967896','lexi-content-ref-10553856'])">Ref</a></span>). <b>Note:</b> Most patients will recover respiratory function and muscle strength within 9 to 10 minutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26967896','lexi-content-ref-10553856']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26967896','lexi-content-ref-10553856'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="75d1b129-8032-4e57-a035-27b22d97af93">Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation (as adjunct to general anesthesia):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM:</b> Up to 3 to 4 mg/kg, maximum total dose: 150 mg.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">Intubation: 0.6 mg/kg (range: 0.3 to 1.1 mg/kg).</p>
<p style="text-indent:-2em;margin-left:6em;">Rapid-sequence intubation (off-label dosing): 1 to 1.5 mg/kg (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14576536','lexi-content-ref-16368821','lexi-content-ref-16243994','lexi-content-ref-9257203']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14576536','lexi-content-ref-16368821','lexi-content-ref-16243994','lexi-content-ref-9257203'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Long surgical procedures (intermittent administration): Initial: 0.3 to 1.1 mg/kg; administer 0.04 to 0.07 mg/kg at appropriate intervals as needed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Pretreatment with atropine may reduce occurrence of bradycardia. Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment is used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1'])">Ref</a></span>). When the cumulative dose of succinylcholine exceeds 2 to 4 mg/kg under general anesthesia, transition from a phase I to a phase II block may occur. If phase II block is suspected, diagnosis should be confirmed by peripheral nerve stimulation prior to administration of an anticholinesterase drug (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7193996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7193996'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990709"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988051"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doo drugH1Div" id="F20330601"><span class="drugH1">Dosing: Obesity: Adult</span>
<p style="text-indent:0em;display:inline">The recommendations for dosing in patients with obesity are based upon the best available evidence and clinical expertise. Senior Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</p>
<p style="text-indent:-2em;margin-left:2em;">Class 1, 2 or 3 obesity (BMI ≥30 kg/m<sup>2</sup>): <b>IV, IM:</b> No dosage adjustment necessary; use <b>actual body weight</b> for weight-based dose calculations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428539','lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428539','lexi-content-ref-Expert.DOO'])">Ref</a></span>). In patients with extreme obesity (eg, BMI &gt;60 kg/m<sup>2</sup>), consider using <b>adjusted body weight</b> for weight-based dosing calculations; however, intubating conditions may be less than optimal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOO']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOO'])">Ref</a></span>). Refer to adult dosing for indication-specific doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Rationale for recommendations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Data evaluating succinylcholine dosing in extreme obesity originate from studies conducted in the surgery setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7091721','lexi-content-ref-16428539','lexi-content-ref-10702440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7091721','lexi-content-ref-16428539','lexi-content-ref-10702440'])">Ref</a></span>). In 1 study with healthy subjects, a positive correlation was noted between pseudocholinesterase activity and BSA, weight, and BMI. A similar duration of effect was observed for succinylcholine doses based on actual body weight, regardless of weight, after 1 mg/kg was administered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7091721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7091721'])">Ref</a></span>). A retrospective cohort study suggests patients with obesity (≥120 kg) received a suboptimal dose (≤1 mg/kg) and subsequently had decreased first-pass success with rapid sequence intubation in the emergency department (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28814478']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28814478'])">Ref</a></span>). A randomized, controlled trial evaluating succinylcholine weight-based dosing found use of actual body weight resulted in more favorable intubating conditions compared to using ideal body weight or lean body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16428539']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16428539'])">Ref</a></span>).</p></div>
<div class="block doe drugH1Div" id="F223435"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F223453"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12809" href="/d/html/12809.html" rel="external">see "Succinylcholine (suxamethonium): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to effect; doses will vary due to interpatient variability. To avoid prolonged neuromuscular blockade, use carefully and/or consider dose reduction in patients with reduced plasma cholinesterase activity due to genetic abnormalities of plasma cholinesterase or when associated with other conditions (eg, electrolyte abnormalities, neuromuscular disease, severe liver or kidney disease, malignant tumors). Initial dose of succinylcholine must be increased when nondepolarizing agent pretreatment used because of the antagonism between succinylcholine and nondepolarizing neuromuscular-blocking agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Miller.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Miller.1'])">Ref</a></span>). Because of the risk of adverse effects including malignant hyperthermia and cardiac arrhythmias, surgical or long-term paralytic use (ie, continuous IV infusion) is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.1','lexi-content-ref-10616334']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.1','lexi-content-ref-10616334'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f24df40b-61dd-4c3e-8593-6eea50bfdd7e">Endotracheal intubation, emergent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endotracheal intubation, emergent (eg, rapid sequence intubation): Note:</b> To reduce the risk of bradycardia or asystole, premedication with atropine recommended prior to IV succinylcholine doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cote.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cote.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Doses in obese patients should be calculated using total body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.1','lexi-content-ref-10702440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.1','lexi-content-ref-10702440'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IM:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &lt;6 months: Limited data available: 4 to 5 mg/kg; pharmacokinetic data suggests that young infants typically require doses on the higher end of this range (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cote.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cote.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≥6 months and Children: 4 mg/kg; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-7294424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-7294424'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: 3 to 4 mg/kg; maximum dose: 150 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">IV:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants ≤6 months: IV: 2 to 3 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-10446832','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-10446832','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Infants &gt;6 months: IV: 1 to 2 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Manu.1'])">Ref</a></span>); doses up to 3 mg/kg/dose have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cote.1','lexi-content-ref-10446832']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cote.1','lexi-content-ref-10446832'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Children: IV: 1 to 2 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-10446832','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-Cote.1','lexi-content-ref-10446832','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Adolescents: IV: 1 to 1.5 mg/kg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31871244','lexi-content-ref-23188232','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31871244','lexi-content-ref-23188232','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51160272"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51160273"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F223403"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Abnormal T waves on ECG (peaked T-wave), asystole, bradycardia (higher with second dose; more frequent in children), cardiac arrhythmia, hypertension, hypotension, tachycardia, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Sialorrhea</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reactions</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Malignant hyperthermia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Fasciculations, jaw tightness, postoperative myalgia, rhabdomyolysis (can be acute; with possible myoglobinuric acute renal failure), state of neuromuscular blockade (with prolonged use: transition from phase I to phase II block)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Increased intraocular pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, respiratory depression</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Tachyphylaxis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Nonimmune anaphylaxis</p></div>
<div class="block coi drugH1Div" id="F223418"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Hypersensitivity to succinylcholine or any component of the formulation; known or suspected genetic susceptibility to malignant hyperthermia; skeletal muscle myopathies; use after the acute phase of injury following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury.</p></div>
<div class="block war drugH1Div" id="F223401"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylaxis: Severe anaphylactic reactions (some life-threatening and fatal) have been reported; immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during use. Use caution in patients with previous anaphylactic reactions to other neuromuscular blocking agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bradycardia: Risk of bradycardia may be increased with second dose and may occur more in children. Occurrence may be reduced by pretreating with anticholinergic agents (eg, atropine).</p>
<p style="text-indent:-2em;margin-left:4em;">• Increased intraocular pressure: May increase intraocular pressure (IOP); avoid use in patients in which an increase in IOP is undesirable (eg, narrow-angle glaucoma, penetrating eye injuries) (Cunningham 1986; Gropper 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial pressure: May cause a transient increase in intracranial pressure (adequate anesthetic induction prior to administration of succinylcholine will minimize this effect).</p>
<p style="text-indent:-2em;margin-left:4em;">• Intragastric pressure: May increase intragastric pressure, which could result in regurgitation and possible aspiration of stomach contents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignant hyperthermia: May trigger malignant hyperthermia; some reported cases have been fatal. Risk may be increased with concomitant administration of succinylcholine and volatile anesthetic agents and patients with genetic factors or family history of malignant hyperthermia, including ryanodine receptor or dihydropyridine receptor inherited variants. Signs of malignant hyperthermia may include arrhythmias, cyanosis, hemodynamic instability, hypercapnia, hyperthermia, hypovolemia, hypoxia, muscle rigidity, tachycardia, and tachypnea; coagulopathies, renal failure, and skin mottling may also occur. If malignant hyperthermia is suspected, discontinue triggering agents and institute appropriate therapy (eg, dantrolene) and other supportive measures.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neuromuscular cross-sensitivity: Cross-sensitivity with other neuromuscular-blocking agents may occur; use extreme caution in patients with previous anaphylactic reactions to other neuromuscular-blocking agents.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vagal tone: May increase vagal tone.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Burn injury: Use with caution in patients with extensive or severe burns; risk of hyperkalemia is increased following injury. Onset of time and duration of risk are variable, but risk is generally greatest 7 to 10 days after injury. Resistance may occur in burn patients (≥20% of total body surface area), usually several days after the injury, and may persist for several months after wound healing (Han 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>antagonize</i> neuromuscular blockade (decreased paralysis): Respiratory alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, muscle trauma, and diabetes mellitus may result in antagonism of neuromuscular blockade (ACCM/SCCM/ASHP [Murray 2002]; Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Conditions that may <i>potentiate</i> neuromuscular blockade (increased paralysis): Electrolyte abnormalities (eg, severe hypocalcemia, severe hypokalemia, hypermagnesemia), neuromuscular diseases, metabolic acidosis, respiratory acidosis, Eaton-Lambert syndrome, and myasthenia gravis may result in potentiation of neuromuscular blockade (Greenberg 2013; Miller 2010; Naguib 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Fractures/muscle spasm: Use with caution in patients with fractures or muscle spasm; initial muscle fasciculations may cause additional trauma.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperkalemia: Use with extreme caution in patients with preexisting hyperkalemia. Potentially severe hyperkalemia (increase up to ~0.5 mEq/L) may develop in patients with chronic abdominal infections, burn injuries, multiple trauma/crush injuries, extensive denervation of skeletal muscle, upper motor neuron injury, subarachnoid hemorrhage, or conditions which cause degeneration of the central and peripheral nervous system (Raman 1997; Roberts 2018; Weintraub 1969). However, in patients with a predisposition to hyperkalemia (eg, rhabdomyolysis, major trauma, burns) the increase can be &gt;5 mEq/L, which may cause serious dysrhythmias (Gronert 2001; Roberts 2018).</p>
<p style="text-indent:-2em;margin-left:4em;">• Plasma pseudocholinesterase disorders: Metabolized by plasma cholinesterase; use with caution (if at all) in patients suspected of being homozygous for the atypical plasma cholinesterase gene. Plasma cholinesterase activity may also be reduced by burns, anemia, decompensated heart disease, infections, malignant tumors, myxedema, pregnancy, severe hepatic or renal dysfunction, peptic ulcer, and certain medications and chemicals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution in older adults, effects and duration are more variable.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Maintenance of an adequate airway and respiratory support is critical. All patients should receive eye care including liberal use of lubricating drops, gel, or ointment and eyelids should remain closed during continuous neuromuscular blockade to protect against damage to the cornea (ulceration and dryness).</p>
<p style="text-indent:-2em;margin-left:4em;">• Experienced personnel: Should be administered by adequately trained individuals familiar with its use.</p>
<p style="text-indent:-2em;margin-left:4em;">• Risk of medication errors: Accidental administration may be fatal. Confirm proper selection of intended product, store vial so the cap and ferrule are intact and the possibility of selecting the wrong product is minimized, and ensure that the intended dose is clearly labeled and communicated, when applicable.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878641"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In children and adolescents, rare reports of acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death have been reported in children with undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy. This syndrome presents as peaked T-waves and sudden cardiac arrest within minutes after the administration of succinylcholine. Bradycardia has been reported in both children and adults following succinylcholine and may progress to asystole; a higher incidence and severity of bradycardia occurs in pediatric patients. Bradycardia commonly occurs after initial doses &gt;1.5 mg/kg in children; both children and adults are at risk following repeat doses. Also, if sudden cardiac arrest occurs immediately after administration of succinylcholine, consider hyperkalemia as potential etiology and manage accordingly. In neonates, some experts consider hyperkalemia a contraindication for use (AAP [Kumar 2010]).</p></div>
<div class="block foc drugH1Div" id="F223412"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anectine: 20 mg/mL (10 mL) [contains methylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Quelicin: 20 mg/mL (10 mL) [contains methylparaben, propylparaben]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Prefilled Syringe, Injection, as chloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/5 mL (5 mL)</p></div>
<div class="block geq drugH1Div" id="F223397"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F16323901"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Anectine Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $2.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Quelicin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $2.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Succinylcholine Chloride Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.40 - $2.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution Prefilled Syringe</b> (Succinylcholine Chloride Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/5 mL (per mL): $6.00</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868300"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection, as chloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Quelicin Chloride: 20 mg/mL (10 mL, 20 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (10 mL, 20 mL)</p></div>
<div class="block adm drugH1Div" id="F223415"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IM:</b> Administer deep IM only when IV access is not available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> May be administered undiluted by rapid IV injection.</p>
<p style="text-indent:-2em;margin-left:2em;">Prefilled syringe: For single use only. Expel air bubble and connect to appropriate injection connection; do not add any other fluid to syringe.</p></div>
<div class="block admp drugH1Div" id="F52613884"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: </p>
<p style="text-indent:-2em;margin-left:2em;">IM:  Injection should be made deeply. Use only when IV access is not available.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: May be administered undiluted by rapid IV injection.</p></div>
<div class="block use drugH1Div" id="F223413"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Neuromuscular blockade for endotracheal intubation, surgery, or mechanical ventilation:</b> As an adjunct to general anesthesia to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation in adequately sedated patients.</p></div>
<div class="block off-label drugH1Div" id="F25744912"><span class="drugH1">Use: Off-Label: Adult</span><p>Electroconvulsive therapy, muscle relaxation</p></div>
<div class="block mst drugH1Div" id="F2973356"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">According to the 2020 to 2021 <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>, neuromuscular blockers should be segregated, sequestered, and differentiated from all other medication wherever they are stored. This includes:</p>
<p style="text-indent:-2em;margin-left:4em;">Only storing in places within the hospital that they are routinely used.</p>
<p style="text-indent:-2em;margin-left:4em;">Placing in sealed boxes or in rapid sequence intubation kits (preferred).</p>
<p style="text-indent:-2em;margin-left:4em;">Limiting availability in automated dispensing cabinets to perioperative, labor and delivery, critical care, and emergency departments only.</p>
<p style="text-indent:-2em;margin-left:4em;">Placing in separate lidded containers within the pharmacy refrigerator or other isolated pharmacy storage area.</p>
<p style="text-indent:-2em;margin-left:4em;">Affixing an auxiliary label to clearly communicate respiratory paralysis will occur and ventilation required on all storage bins and/or automated dispensing pockets/drawers (exception anesthesia-prepared syringes) stating one of the following:</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Warning: Causes Respiratory Arrest – Patient Must Be Ventilated </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Warning: Paralyzing Agent – Causes Respiratory Arrest </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Warning: Causes Respiratory Paralysis – Patient Must Be Ventilated</b></p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Quelicin [US, Brazil, Canada, Indonesia] may be confused with Keflin brand name for cefalotin [Argentina, Brazil, Mexico, Netherlands, Norway]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300086"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F223405"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May enhance the therapeutic effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprotinin: May enhance the therapeutic effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacitracin (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bambuterol: May enhance the therapeutic effect of Succinylcholine. Bambuterol may increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Botulinum Toxin-Containing Products: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capreomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cardiac Glycosides: Neuromuscular-Blocking Agents may enhance the arrhythmogenic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clindamycin (Topical): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colistimethate: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of these products. Monitor for deeper, prolonged neuromuscular-blocking effects (respiratory paralysis) in patients receiving concomitant neuromuscular-blocking agents and colistimethate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloPHOSphamide: May increase the serum concentration of Succinylcholine. Management: Consider alternatives to succinylcholine in patients who have received cyclophosphamide in the past 10 days. If combined, consider reduced succinylcholine doses and close monitoring for increased and prolonged neuromuscular blocking effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desflurane: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Echothiophate Iodide: May increase the serum concentration of Succinylcholine. Management: For patients receiving echothiophate iodide eye drops, consider using a neuromuscular-blocking agents other than succinylcholine. If succinylcholine is used, consider a reduced dose, and monitor for enhanced/prolonged effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Estrogen Derivatives: May increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Isoflurane: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lincosamide Antibiotics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Local Anesthetics: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Loop Diuretics may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Minocycline (Systemic): May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: Succinylcholine may enhance the bradycardic effect of Opioid Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxytocin: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenelzine: May enhance the neuromuscular-blocking effect of Succinylcholine. Management: Consider a lower initial succinylcholine dose in patients taking phenelzine, or those who have taken phenelzine within the previous 2 weeks. Monitor for increased succinylcholine effects (eg, prolonged apnea) in patients who recently received phenelzine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: May enhance the adverse/toxic effect of Neuromuscular-Blocking Agents. Specifically, anaphylaxis has been reported.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polymyxin B: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. Management: If possible, avoid concomitant use of neuromuscular-blocking agents and polymyxin B. If concomitant use cannot be avoided, monitor for deeper, prolonged neuromuscular-blocking effects (eg, respiratory paralysis) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Procainamide: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Promazine: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNINE: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertraline: May increase the serum concentration of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terbutaline: May enhance the neuromuscular-blocking effect of Succinylcholine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vancomycin: May enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F54342583"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Sensitivity to succinylcholine may be increased due to a decrease in plasma cholinesterase activity in patients taking chronic oral contraceptives.</p></div>
<div class="block pri drugH1Div" id="F5023968"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Succinylcholine crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of major congenital anomalies has not been observed. Sensitivity to succinylcholine may be increased due to a ~24% decrease in plasma cholinesterase activity during pregnancy and several days postpartum; prolonged maternal apnea may be observed. Newborns of mothers with atypical plasma cholinesterase or those exposed to repeated or high doses of succinylcholine during cesarean delivery should be monitored for apnea and flaccidity.</p></div>
<div class="block brc drugH1Div" id="F16571287"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if succinylcholine is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F223410"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs (heart rate, BP, respiratory rate); oxygen saturation and end-tidal carbon dioxide (if available) (Roberts 2018); degree of muscle paralysis (eg, presence of spontaneous movement, ventilator asynchrony, shivering, and consider use of a peripheral nerve stimulator with train of four monitoring along with clinical assessments); serum potassium and calcium.</p></div>
<div class="block pha drugH1Div" id="F223400"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Acts similar to acetylcholine, produces depolarization of the motor endplate at the myoneural junction which causes sustained flaccid skeletal muscle paralysis produced by state of accommodation that develops in adjacent excitable muscle membranes</p></div>
<div class="block phk drugH1Div" id="F223417"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Dependent on route, age, and dose; data suggest faster onset with higher doses (Coté 2019):</p>
<p style="text-indent:-2em;margin-left:4em;">IM: Infants and Children: 3 to 4 minutes (Liu 1981); Adults: 2 to 3 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">IV:</p>
<p style="text-indent:-2em;margin-left:6em;">Neonates and Infants: ~30 seconds (range: 19 to 40 seconds [dose: 2 to 4 mg/kg]) (Meakin 1990).</p>
<p style="text-indent:-2em;margin-left:6em;">Children and Adolescents: 35 to 55 seconds (Coté 2019).</p>
<p style="text-indent:-2em;margin-left:6em;">Adults: Flaccid paralysis: &lt;60 seconds.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Dependent on route, age, and dose; hypothermia may prolong the duration of action.</p>
<p style="text-indent:-2em;margin-left:4em;">IM: 10 to 30 minutes; Observed to be shorter in infants than children.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: ~4 to 10 minutes; Faster recovery rate in infants and children compared to adults (Fisher 1975; Greenberg 2013).</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub> higher in neonates and infants due to larger ECF volume; higher IV doses necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Rapidly hydrolyzed by plasma pseudocholinesterase to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (~10% excreted unchanged).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F223420"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Midarine</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Succinilcolina gray</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lysthenon</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Rapilax</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Celocurine | Myoplegine</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Quelicin | Succitrat</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Suxamethonium</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Quelicin</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Lysthenon | Pantolax | Succicuran</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Quelicin</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Sukolin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Succinyl choline</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Anectine | Mioflex</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sukolin | Suxamethonium ethypharm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Biocodex suxamethonium | Suxamethonium aguettant | Suxamethonium ethypharm</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Anectine | Scoline</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Sukolin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Anectine | Suxamethonium</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Suxim</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Succicholine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Midarine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Suxamethonium</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Myoplegine</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Anectine</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Curalest | Suxamethoniumchloride CF</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Lysthenon | Suxamethonium chloride dihydrate ethypharm | Suxamethonium chloride martindale</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Ethicholine | Succinolin</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Anectine</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Succinyl | Suxam</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anectine | Lysthenon | Succinycholinjodid</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Anectine | Quelicin | Quelicin-1000 | Succinyl choline</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Suxametonio</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lysthenon | Midarine | Succinolin</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Suksametonij biolek</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Celocurin</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Succinylcholin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lysthenon</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Scoline | Succinyl</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Micro-suxamethonium | Pharma Q Suxamethonium | Q-med suxamethonium | Suxamethonium</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Anectine.1">
<a name="Anectine.1"></a>Anectine (succinylcholine chloride) injection, USP [prescribing information]. Lehi, UT: Civica Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23188232">
<a name="23188232"></a>Ballow SL, Kaups KL, Anderson S, Chang M. A standardized rapid sequence intubation protocol facilitates airway management in critically injured patients. <i>J Trauma Acute Care Surg</i>. 2012;73(6):1401-1405.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/23188232/pubmed" id="23188232" target="_blank">23188232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7091721">
<a name="7091721"></a>Bentley JB, Borel JD, Vaughan RW, Gandolfi AJ. Weight, pseudocholinesterase activity, and succinylcholine requirement. <i>Anesthesiology</i>. 1982;57(1):48-49. doi:10.1097/00000542-198207000-00014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/7091721/pubmed" id="7091721" target="_blank">7091721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14724877">
<a name="14724877"></a>Brunette DD. Resuscitation of the Morbidly Obese Patient. <i>Am J Emerg Med</i>. 2004;22(1):40-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/14724877/pubmed" id="14724877" target="_blank">14724877</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20231228">
<a name="20231228"></a>Choong K, AlFaleh K, Doucette J, et al. Remifentanil for endotracheal intubation in neonates: a randomised controlled trial. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2010;95(2):F80-84.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/20231228/pubmed" id="20231228" target="_blank">20231228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1130737">
<a name="1130737"></a>Cook DR, Fisher CG. Neuromuscular blocking effects of succinylcholine in infants and children. <i>Anesthesiology</i>. 1975;42(6):662-665.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/1130737/pubmed" id="1130737" target="_blank">1130737</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2827933">
<a name="2827933"></a>Costarino AT, Polin RA. Neuromuscular relaxants in the neonate. <i>Clin Perinatol</i>. 1987;14(4):965-989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/2827933/pubmed" id="2827933" target="_blank">2827933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cote.1">
<a name="Cote.1"></a>Coté CJ, Lerman J, Anderson B, eds. <i>A Practice of Anesthesia for Infants and Children</i>. 6th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3516335">
<a name="3516335"></a>Cunningham AJ, Barry P. Intraocular pressure--physiology and implications for anaesthetic management. <i>Can Anaesth Soc J</i>. 1986;33(2):195-208. doi:10.1007/BF03010831<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/3516335/pubmed" id="3516335" target="_blank">3516335</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11973219">
<a name="11973219"></a>Ding Z, White PF. Anesthesia for electroconvulsive therapy. <i>Anesth Analg</i>. 2002;94(5):1351-1364.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/11973219/pubmed" id="11973219" target="_blank">11973219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOO">
<a name="Expert.DOO"></a>Expert opinion. Senior Obesity Editorial Team: Jeffrey F. Barletta, PharmD, FCCM; Manjunath P. Pai, PharmD, FCP; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10616334">
<a name="10616334"></a>Fisher DM. Neuromuscular blocking agents in paediatric anaesthesia. <i>Br J Anaesth</i>. 1999;83(1):58-64.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/10616334/pubmed" id="10616334" target="_blank">10616334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485450">
<a name="17485450"></a>Ghanta S, Abdel-Latif ME, Lui K, Ravindranathan H, Awad J, Oei J. Propofol compared with the morphine, atropine, and suxamethonium regimen as induction agents for neonatal endotracheal intubation: a randomized, controlled trial. <i>Pediatrics</i>. 2007;119(6):e1248-1255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/17485450/pubmed" id="17485450" target="_blank">17485450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23591211">
<a name="23591211"></a>Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? <i>Crit Care Med</i>. 2013;41(5):1332-1344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/23591211/pubmed" id="23591211" target="_blank">23591211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11374616">
<a name="11374616"></a>Gronert GA. Cardiac arrest after succinylcholine: mortality greater with rhabdomyolysis than receptor upregulation. <i>Anesthesiology</i>. 2001;94(3):523-529. doi:10.1097/00000542-200103000-00026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/11374616/pubmed" id="11374616" target="_blank">11374616</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Gropper.1">
<a name="Gropper.1"></a>Gropper M, Eriksson L, Fleisher L, Wiener-Kronish J, Cohen N, Leslie K. <i>Miller's Anesthesia</i>. 9th ed. Elsevier; 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19029093">
<a name="19029093"></a>Han TH, Martyn JA. Onset and effectiveness of rocuronium for rapid onset of paralysis in patients with major burns: priming or large bolus. <i>Br J Anaesth</i>. 2009;102(1):55-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/19029093/pubmed" id="19029093" target="_blank">19029093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7193996">
<a name="7193996"></a>Hilgenberg JC, Stoelting RK. Characteristics of succinylcholine-produced phase II neuromuscular block during enflurane, halothane, and fentanyl anesthesia. <i>Anesth Analg.</i> 1981;60(4):192-196.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/7193996/pubmed" id="7193996" target="_blank">7193996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ISMP.1">
<a name="ISMP.1"></a>Institute for Safe Medicine Practices (ISMP). <i>ISMP Targeted Medication Safety Best Practices for Hospitals</i>. https://www.ismp.org/sites/default/files/attachments/2020-02/2020-2021%20TMSBP-%20FINAL_1.pdf. Published February 21, 2020. Accessed August 4, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20176672">
<a name="20176672"></a>Kumar P, Denson SE, Mancuso TJ, et al. Premedication for Nonemergency Endotracheal Intubation in the Neonate. <i>Pediatrics</i>. 2010;125(3):608-615.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/20176672/pubmed" id="20176672" target="_blank">20176672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16428539">
<a name="16428539"></a>Lemmens HJ, Brodsky JB. The dose of succinylcholine in morbid obesity. <i>Anesth Analg</i>. 2006;102(2):438-442. doi:10.1213/01.ane.0000194876.00551.0e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/16428539/pubmed" id="16428539" target="_blank">16428539</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19307222">
<a name="19307222"></a>Lemyre B, Cheng R, Gaboury I. Atropine, fentanyl and succinylcholine for non-urgent intubations in newborns. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2009;94(6):F439-F442.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/19307222/pubmed" id="19307222" target="_blank">19307222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7294424">
<a name="7294424"></a>Liu LM, DeCook TH, Goudsouzian NG, Ryan JF, Liu PL. Dose response to intramuscular succinylcholine in children.<i> Anesthesiology</i>. 1981;55(5):599-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/7294424/pubmed" id="7294424" target="_blank">7294424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10446832">
<a name="10446832"></a>Martin LD, Bratton SL, O'Rourke PP. Clinical uses and controversies of neuromuscular blocking agents in infants and children. <i>Crit Care Med</i>. 1999;27(7):1358-1368. doi:10.1097/00003246-199907000-00030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/10446832/pubmed" id="10446832" target="_blank">10446832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30567922">
<a name="30567922"></a>McPherson C. Premedication for endotracheal intubation in the neonate. <i>Neonatal Netw</i>. 2018;37(4):238-247. doi:10.1891/0730-0832.37.4.238<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/30567922/pubmed" id="30567922" target="_blank">30567922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2265051">
<a name="2265051"></a>Meakin G, Walker RW, Dearlove OR. Myotonic and neuromuscular blocking effects of increased doses of suxamethonium in infants and children. <i>Br J Anaesth</i>. 1990;65(6):816-818.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/2265051/pubmed" id="2265051" target="_blank">2265051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Miller.1">
<a name="Miller.1"></a>Miller RD, ed. Miller’s Anesthesia, 7th ed. Philadelphia PA: Churchill Livingstone; 2010.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26967896">
<a name="26967896"></a>Mirzakhani H, Guchelaar HJ, Welch CA, et al. Minimum effective doses of succinylcholine and rocuronium during electroconvulsive therapy: a prospective, randomized, crossover trial. <i>Anesth Analg</i>. 2016;123(3):587-596. doi:10.1213/ANE.0000000000001218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/26967896/pubmed" id="26967896" target="_blank">26967896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10553856">
<a name="10553856"></a>Murali N, Saravanan ES, Ramesh VJ, et al. An intrasubject comparison of two doses of succinylcholine in modified electroconvulsive therapy. <i>Anesth Analg</i>. 1999;89(5):1301-1304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/10553856/pubmed" id="10553856" target="_blank">10553856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11902255">
<a name="11902255"></a>Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2002;30(1):142-156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/11902255/pubmed" id="11902255" target="_blank">11902255</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27755068">
<a name="27755068"></a>Murray MJ, DeBlock H, Erstad B, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. <i>Crit Care Med</i>. 2016;44(11):2079-2103. doi:10.1097/CCM.0000000000002027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/27755068/pubmed" id="27755068" target="_blank">27755068</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11753022">
<a name="11753022"></a>Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. <i>Anesthesiology</i>. 2002;96(1):202-231.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/11753022/pubmed" id="11753022" target="_blank">11753022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16368821">
<a name="16368821"></a>Naguib M, Samarkandi AH, El-Din ME, Abdullah K, Khaled M, Alharby SW. The dose of succinylcholine required for excellent endotracheal intubating conditions. <i>Anesth Analg</i>. 2006;102(1):151-155. doi:10.1213/01.ANE.0000181320.88283.BE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/16368821/pubmed" id="16368821" target="_blank">16368821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14576536">
<a name="14576536"></a>Naguib M, Samarkandi A, Riad W, Alharby SW. Optimal dose of succinylcholine revisited. <i>Anesthesiology</i>. 2003;99(5):1045-1049. doi:10.1097/00000542-200311000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/14576536/pubmed" id="14576536" target="_blank">14576536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28814478">
<a name="28814478"></a>Patanwala AE, Sakles JC. Effect of patient weight on first pass success and neuromuscular blocking agent dosing for rapid sequence intubation in the emergency department. <i>Emerg Med J</i>. 2017;34(11):739-743. doi:10.1136/emermed-2017-206762<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/28814478/pubmed" id="28814478" target="_blank">28814478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Quelicin.1">
<a name="Quelicin.1"></a>Quelicin (succinylcholine chloride) injection [prescribing information]. Lake Forest, IL: Hospira Inc; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9161744">
<a name="9161744"></a>Raman SK, San WM. Fasciculations, myalgia and biochemical changes following succinylcholine with atracurium and lidocaine pretreatment. <i>Can J Anaesth</i>. 1997;44(5, pt 1):498-502. doi:10.1007/BF03011938<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/9161744/pubmed" id="9161744" target="_blank">9161744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roberts.1">
<a name="Roberts.1"></a>Roberts J. <i>Roberts and Hedges’ Clinical Procedures in Emergency Medicine and Acute Care</i>. 7th ed. Elsevier; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10702440">
<a name="10702440"></a>Rose JB, Theroux MC, Katz MS. The potency of succinylcholine in obese adolescents. <i>Anesth Analg</i>. 2000;90(3):576-578. doi:10.1097/00000539-200003000-00015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/10702440/pubmed" id="10702440" target="_blank">10702440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3414714">
<a name="3414714"></a>Ross MB. Additional Stability Guidelines for Routinely Refrigerated Drug Products. <i>Am J Hosp Pharm</i>. 1988;45(7):1498-1499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/3414714/pubmed" id="3414714" target="_blank">3414714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Roy.1">
<a name="Roy.1"></a>Roy JJ, Boismenu D, Mamer OA, et al. Room Temperature Stability of Injectable Succinylcholine Dichloride. <i>Int J Pharm Compound</i>. 2008;12(1): 83-85.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31871244">
<a name="31871244"></a>Shenoi RP, Timm N; Committee on Drugs; Committee on Pediatric Emergency Medicine. Drugs used to treat pediatric emergencies. <i>Pediatrics</i>. 2020;145(1):e20193450. doi:10.1542/peds.2019-3450<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/31871244/pubmed" id="31871244" target="_blank">31871244</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243994">
<a name="16243994"></a>Sluga M, Ummenhofer W, Studer W, et al. Rocuronium Versus Succinylcholine for Rapid Sequence Induction of Anesthesia and Endotracheal Intubation: A Prospective, Randomized Trial in Emergent Cases. <i>Anesth Analg</i>. 2005;101(5):1356-1361.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/16243994/pubmed" id="16243994" target="_blank">16243994</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Storms.1">
<a name="Storms.1"></a>Storms ML, Stewart JT, Warren FW. Stability of Succinylcholine Chloride Injection at Ambient Temperature and 4°C in Polypropylene Syringes. <i>Int J Pharm Compound</i>. 2003;7(1):68-70.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hikma.1">
<a name="Hikma.1"></a>Succinylcholine chloride injection solution [prescribing information]. Berkeley Heights, NJ: Hikma Pharmaceuticals USA; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5365522">
<a name="5365522"></a>Weintraub HD, Heisterkamp DV, Cooperman LH. Changes in plasma potassium concentration after depolarizing blockers in anaesthetized man. <i>Br J Anaesth</i>. 1969;41(12):1048-1052. doi:10.1093/bja/41.12.1048<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/5365522/pubmed" id="5365522" target="_blank">5365522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9257203">
<a name="9257203"></a>Weiss JH, Gratz I, Goldberg ME, et al. Double-Blind Comparison of Two Doses of Rocuronium and Succinylcholine for Rapid-Sequence Intubation. <i>J Clin Anesth</i>. 1997;9(5):379-382.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/succinylcholine-suxamethonium-drug-information/abstract-text/9257203/pubmed" id="9257203" target="_blank">9257203</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9952 Version 462.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
